Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Novavax Starts a Late-Stage Coronavirus Vaccine Clinical Trial

By Brian Orelli, PhD - Dec 28, 2020 at 2:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better late than never.

After running into some manufacturing issues, Novavax ( NVAX 2.59% ) is finally starting a phase 3 clinical trial for its coronavirus vaccine, NVX-CoV2373, in the U.S. and Mexico. The study, dubbed Prevent-19, will enroll 30,000 participants at 115 sites.

The biotech trails Moderna ( MRNA -0.74% ), BioNTech ( BNTX 1.88% ), and Pfizer ( PFE 0.97% ), which have already gotten their coronavirus vaccines authorized by the Food and Drug Administration. Unlike those mRNA-based vaccines, NVX-CoV2373 is a protein from the novel coronavirus put on the outside of a nanoparticle.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Novavax is shooting to have at least 25% of the participants be 65 or older. To encourage people to join the study, Novavax will give the vaccine to two-thirds of the participants instead of half of them, as other vaccine makers have done. Nevertheless it may still be hard to convince people currently eligible to receive the Moderna or the BioNTech/Pfizer vaccine to join a study when there's still a one-in-three chance of getting a placebo. 

Fortunately, Novavax also has a 15,000-participant phase 3 clinical trial in the U.K. that completed enrollment last month, so even if the older age group ends up being underrepresented in the U.S. study, it'll have some data on whether the vaccine can protect older adults.

While Novavax is clearly late to the party, NVX-CoV2373 could still capture some market share if the vaccine is as effective, especially in rural areas, because it can be stored in a refrigerator. Moderna's vaccine needs to be frozen and BioNTech and Pfizer's vaccine has to be kept at ultra-cold temperatures.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$186.45 (2.59%) $4.70
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.90 (0.97%) $0.50
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$281.30 (-0.74%) $-2.10
BioNTech SE Stock Quote
BioNTech SE
BNTX
$297.44 (1.88%) $5.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
145%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.